OncoMatch/Clinical Trials/NCT07203729
The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
Is NCT07203729 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Trastuzumab Rezetecan and Chemotherapy of Physician's Choice for her2-low unresectable/metastatic breast cancer complicated with visceral crisis.
Treatment: Trastuzumab Rezetecan · Chemotherapy of Physician's Choice — The goal of this clinical trial is to learn if Trastuzumab Rezetecan (SHR-A1811) is safe and tolerable for patients with HER2-Low unresectable/metastatic breast cancer complicated with visceral crisis. Participants will take Trastuzumab Rezetecan every three weeks, until disease progression or intolerable toxicity.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) low expression (low)
Disease stage
Metastatic disease required
Demographics
Prior therapy
Cannot have received: antibody-drug conjugate
Lab requirements
Blood counts
Neutrophil count (ANC) ≥ 1,500/mm³ (1.5 × 10⁹/L); Platelet count (PLT) ≥ 80 ×10^9/L; Hemoglobin (Hb) ≥ 80 g/L
Cardiac function
Severe heart disease or cardiac discomfort, including but not limited to: a) A history of heart failure or systolic dysfunction (LVEF < 50%); b) High-risk angina pectoris requiring treatment or cardiac arrhythmias; c) Clinically significant valvular heart disease; d) ECG findings indicating transmural myocardial infarction; e) Poorly controlled hypertension
Sufficient bone marrow function, defined as follows: a) Neutrophil count (ANC) ≥ 1,500/mm³ (1.5 × 10⁹/L); b) Platelet count (PLT) ≥ 80 ×10^9/L; c) Hemoglobin (Hb) ≥ 80 g/L; Have severe heart disease or cardiac discomfort, including but not limited to the following conditions: a) A history of heart failure or systolic dysfunction (LVEF < 50%); b) High-risk angina pectoris requiring treatment or cardiac arrhythmias; c) Clinically significant valvular heart disease; d) ECG findings indicating transmural myocardial infarction; e) Poorly controlled hypertension.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07203729 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior antibody-drug conjugate disqualifies patients from enrollment.
Does this trial require ERBB2?
Yes, ERBB2 low expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages